Duality Advisers, LP Vir Biotechnology, Inc. Transaction History

Duality Advisers, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$8.6 - $11.9 $54,446 - $75,338	6,331 Added 6.65%	101,479 $1.03 Million
Q4 2023 Feb 01, 2024	SELL	$7.76 - $10.29 $222,890 - $295,559	-28,723 Reduced 23.19%	95,148 $957,000
Q3 2023 Nov 02, 2023	BUY	$9.14 - $24.62 $960,970 - $2.59 Million	105,139 Added 561.28%	123,871 $1.16 Million
Q2 2023 Jul 31, 2023	SELL	$23.2 - $27.29 $702,913 - $826,832	-30,298 Reduced 61.79%	18,732 $459,000
Q1 2023 Jun 27, 2023	SELL	$22.26 - $30.85 $159,314 - $220,793	-7,157 Reduced 12.74%	49,030 $1.14 Million
Q4 2022 Feb 07, 2023	SELL	$19.96 - $28.22 $729,039 - $1.03 Million	-36,525 Reduced 39.4%	56,187 $1.42 Million
Q3 2022 Nov 03, 2022	SELL	$18.26 - $31.1 $432,816 - $737,163	-23,703 Reduced 20.36%	92,712 $1.79 Million
Q2 2022 Aug 08, 2022	BUY	$19.08 - $26.7 $1.12 Million - $1.56 Million	58,520 Added 101.08%	116,415 $2.97 Million
Q1 2022 May 09, 2022	BUY	$21.19 - $40.01 $1.23 Million - $2.32 Million	57,895 New	57,895 $1.49 Million

218

87M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $982M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Duality Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Duality Advisers, LP with notifications on news.